| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





From the * Institute of Veterinary Anatomy,
Histology and Embryology, University of Giessen, Giessen, Germany; the
Department of Urology and Pediatric Urology,
University of Giessen, Giessen, Germany; and the
Endokrinologikum Hamburg, Hamburg,
Germany.
| Correspondence to: Prof Dr Klaus Steger, Klinik für Urologie und Kinderurologie, Rudolf-Buchheim-Straße 7, 35383 Giessen, Germany (e-mail: Klaus.Steger{at}chiru.med.uni-giessen.de). |
| Received for publication June 13, 2006; accepted for publication August 1, 2006. |
| Abstract |
|---|
|
|
|---|
2-F-G-H-Ib and CREM-
2-G-H-Ib) in various
germ cell types during normal and impaired human spermatogenesis. In contrast
to known isoforms, these exhibit a transactivation domain but lack a
kinase-inducible domain (KID) domain resulting in a disruption of the open
reading frame. In the present study, we functionally analyzed these isoforms.
Investigation of both in vitro and in vivo expressed proteins from human
testis RNA suggests that a novel upstream open reading frame in exon
2
is translated from isoform CREM-
2-F-G-H-Ib, giving rise to a
full-length protein. Furthermore, in both isoforms, usage of downstream
adeninethymine-guanines (ATGs) for translation initiation could be observed.
Sequence-specific DNA binding of CREM isoforms was confirmed by
electrophoretic mobility shift assays. Luciferase reporter gene assays in
cells transfected with novel CREM cDNAs demonstrated that protein kinase A
dependent stimulation was inhibited by coexpression of CREM-
2-F-G-H-Ib
but not of CREM-
2-G-H-Ib.
Key words: Alternative splicing, spermatogenesis
, contain the kinase-inducible domain (KID), at least 1 of 2
glutamine-rich transactivation domains (
1,
2), and 1 of 2
alternative DNA-binding domains (DBDI, DBDII), whereas CREM repressor
transcripts consist of the KID domain and 1 of the DNA-binding domains but
lack a transactivation domain (Foulkes et
al, 1992; Walker et al,
1994). The KID is the target for phosphorylation by various
protein kinases, including protein kinase A (PKA), resulting in recruitment of
the coactivator CREB binding protein, while the C-terminus of CREM encodes the
bZIP region, consisting of the basic region as the sequence-specific
DNA-binding interface and the leucine zipper, which accommodates dimerization
of members of the bZIP family of proteins
(Montminy, 1997;
Vinson et al, 2002).
|
expression (Weinbauer et al,
1998; Steger et al,
1999) and inaccurately spliced CREM transcripts
(Behr and Weinbauer, 2000;
Blöcher et al, 2005). In a
recent study, we demonstrated expression of 2 novel CREM isoforms,
characterized by exons
2-F-G-H and
2-G-H, in various germ cell
types during normal and impaired spermatogenesis
(Blöcher et al, 2003;
Blöcher et al, 2005). The
aim of the present study was to functionally analyze these isoforms.
| Materials and Methods |
|---|
|
|
|---|
2-F-G-H-Ib and CREM-
2-G-H-Ib.
Isoforms CREM-
2-E-F-G-H-Ib and CREM-
2-E-F-H-Ib, also designated
CREM-
2-
2-ß and CREM-
2-ß, have been characterized
previously (Gellersen et al,
2002) and were included in the experiments for comparison. First
strand cDNA synthesis was performed using 2 µg of human testis total RNA
(BD Biosciences, Heidelberg, Germany) and oligo d(T)16 primers
(Applied Biosystems, Weiterstadt, Germany) with the Omniscript RT Kit (Qiagen,
Hilden, Germany), according to the manufacturer's protocol. In addition, RNase
inhibitor (Roche, Mannheim, Germany) was added. The polymerase chain reaction
(PCR) amplification contained 5 µL Pfu DNA polymerase 10x
buffer with MgSO4, 1 µL 25 mmol MgCl2, 1 µL dNTP
mix (10 mmol each), 1.25 U Pfu DNA polymerase (all from Promega,
Heidelberg, Germany), 1 µL sense and antisense primers (10 pmol) and 2
µL cDNA in a final volume of 50 µL. The primers used for PCR were:
5'-ACCGAAGTATGGGCACCA-3' (sense, localized in CREM exon
2)
(Gellersen et al, 2002) and
5'-CTAGTAATC(A/T)GTTTTGGGAGA-3' (antisense, localized in CREM exon
Ib, according to the human cDNA sequence)
(Gellersen et al, 2002;
Masquilier et al, 1993). The
thermal cycling conditions were: initial denaturation for 1 minute at
95°C, followed by 35 cycles for 45 seconds at 95°C, 30 seconds at
51°C, 2 minutes at 72°C, and 1 cycle for 5 minutes at 72°C. PCR
products were separated on a 2% agarose gel, purified with the QIAEX II gel
extraction kit (Qiagen) and cloned into pCR-Blunt IITOPO using the Zero
Blunt TOPO PCR Cloning Kit and verified by sequencing (Qiagen). PCR on the
CREM cDNAs in pCR-Blunt IITOPO was then performed with primers
5'-ACCGAAGTATGGGCACCA-3' (sense, localized in exon
2)
(Gellersen et al, 2002) and
5'-TGTATTCTAGATAGTAATC(A/T)GTTTTGGGAGA-3' (antisense, localized in
exon Ib, eliminating the stop codon and adding a Xba I site to the
3'-end of the DBD II) and Pfu DNA polymerase. PCR conditions
were as described above, but no additional MgCl2 was used, and
initial denaturation was extended to 2 minutes. PCR products were restricted
with XbaI and inserted into the EcoRV/XbaI sites of the eukaryotic expression
vector pcDNA/FLAG-His. This vector adds 3'-terminal FLAG- and
6xHis-epitopes to the inserted cDNAs and was generated as follows: from
pcDNA3.1(+) (Invitrogen, Karlsruhe, Germany), the NheI-AflII fragment was
excised from the polylinker to remove the 5' PmeI site and render the
3' PmeI site unique. Into the XbaI/PmeI sites of this modified vector,
pcDNA3.1(P+), a fragment encoding the FLAG- and 6xHis-epitopes was inserted
which had been retrieved from pVP22/FLAG-His by XbaI/PmeI digestion. The
vector pVP22/FLAG-His is a modification of pVP22/myc-His (Invitrogen), from
which the myc epitope had been removed by BstBI/AgeI digestion and replaced by
a double-stranded oligonucleotide which encodes the FLAG epitope (DYKDDDDK)
and destroyed the flanking BstBI/AgeI sites. All CREM inserts were verified by
sequencing (Qiagen).
Protein Preparation![]()
CREM isoforms in pcDNA/FLAG-His (500 ng) were expressed in vitro using the
TNT T7 quick coupled transcription/translation system (Promega) in a final
volume of 25 µL. For in vivo expression, the human uterine myosarcoma cell
line SKUT-1B (HTB 115; American Type Culture Collection, Rockville, Md), was
transiently transfected with CREM expression vectors using Lipofectamine 2000
according to the manufacturer's instructions (Invitrogen). Cells were
maintained in DMEM/Hams F-12 (1:1; Sigma, Deisenhofen, Germany) supplemented
with 10% FCS, 100 IU/mL penicillin, 100 µg/mL streptomycin, and 2 mmol
L-glutamine (PAA Laboratories, GmbH, Cölbe, Germany). For transfection,
2.5 x 105 cells/well were plated in 6-well tissue culture
plates (BD Biosciences) coated with poly-L-lysine (Sigma). A mixture of 2.5
µg CREM/FLAG constructs and 10 µL Lipofectamine 2000 in OptiMEM I
(Invitrogen) was added per well. Medium was changed 16 hours later, and whole
cell protein was harvested 48 hours after transfection in 150 µL
radioimmunoprecipitation buffer (PBS pH 7.4, 1% Igepal [Sigma], 0.1% sodium
dodecyl sulfate [SDS], 0.5% sodium deoxycholate and protease inhibitor
cocktail [Complete; Roche]). Protein concentration was determined with a kit
from BioRad (Munich, Germany).
Western Blot Analysis![]()
In vitro translation products (5 µL) were mixed with 5 µL gel loading
buffer (10 mmol Tris pH 7.2, 10% SDS, 25% 2-mercaptoethanol, 25% glycerol,
0.01% bromophenol blue). Whole cell extract (20 µg) was diluted in Laemmli
gel loading buffer (50 mmol Tris pH 6.8, 100 mmol dithiothreitol, 2% SDS, 0.1%
bromophenol blue, 10% glycerol), and 2-mercaptoethanol was added to 10%. After
denaturation at 95°C, proteins were separated on NuPAGE 4%12%
Bis-Tris gels (Invitrogen) using NuPAGE MES SDS running buffer with
antioxidant (Invitrogen) and subsequently transferred to polyvinylidene
fluoride membrane (Millipore, Schwalbach, Germany) in NuPAGE transfer buffer
(Invitrogen). Immunodetection was performed by enhanced chemiluminescence
(Super Signal West Pico Chemiluminescent Substrate; Pierce, Bonn, Germany)
with monoclonal anti-FLAG M2 antibody (1:1000; Stratagene, Amsterdam, The
Netherlands) and horseradish peroxidase-conjugated goat anti-mouse IgG
F(ab')2-specific secondary antibody (1:5000; Jackson
ImmunoResearch, Hamburg, Germany).
Electrophoretic Mobility Shift Assay![]()
Electrophoretic mobility shift assay (EMSA) was performed using 4 µL in
vitro translation product. A Cy5-labeled double-stranded oligonucleotide with
a consensus CRE (5'-AGAGATTGCCTGACGTCAGAGAGCTAG-3')
served as CRE probe. Proteins were incubated in bandshift buffer (20 mmol Tris
pH 8.0, 1 mmol EDTA, 2.5 mmol DTT, 10% glycerol, 2 mmol MgCl2, 0.1%
Igepal, 50 ng/µL BSA) with 1.6 µg poly(deoxyinosinic acid-deoxycytidylic
acid) for 15 minutes on ice. For competition reactions, 300-fold molar excess
of unlabeled CRE or a mutated CRE sequence
(5'-AGAGATTGCCTGtgGTCAGAGAGCTAG-3') was added. After
addition of 100 fmol CRE probe, incubation was continued on ice for 30
minutes. For supershift studies, 2 µL anti-FLAG M2 antibody (Stratagene)
were added and incubated at room temperature for 30 minutes. Reactions were
resolved on 4% polyacrylamide gels in 0.25x Tris-borate-EDTA buffer
(Invitrogen).
Reporter Gene Assays![]()
Expression vectors for the catalytic (C) subunit of PKA (pcDNA-Cß),
and an inactive mutant thereof (pcDNA-Cßmut), were generated by cloning
the HindIII-XhoI full-length inserts from pRSV-Cß and pRSV-Cßmut,
respectively (kindly provided by R. Maurer, Oregon Health & Science
University, Portland, Ore) (Maurer,
1989), into the same sites of pcDNA3.1(+). For luciferase reporter
gene assays, SKUT-1B cells (0.5x105 cells/well) were plated
in 24-well plates coated with poly-L-lysine. Transient transfections were
carried out in triplicates using Lipofectamine 2000 with 0.04 µg of CREM
expression vectors, 0.5 µg of the cAMP-responsive reporter construct
pCRE/-36rPRL/luc3 (Gellersen et al,
1997), and 0.01 µg of pcDNA-Cß or pcDNA-Cßmut. To
keep the total amount of DNA constant, irrelevant plasmid was added to the
reaction. The medium was replaced 16 hours later, and cells were incubated for
an additional 24 hours before cell extracts were harvested for
chemiluminescent luciferase assay (Promega). Statistical analysis was
performed by one-way ANOVA followed by Bonferroni's post hoc test.
| Results |
|---|
|
|
|---|
2-F-G-H-Ib and CREM-
2-G-H-Ib
(Figure 1), which were cloned
into pcDNA/FLAG-His for expression of proteins with a 3' FLAG tag. For
comparison, the known isoforms CREM-
2-E-F-G-H-Ib and
CREM-
2-E-F-H-Ib (also designated CREM-
2-
2-ß and
CREM-
2-ß, respectively)
(Gellersen et al, 2002;
Figure 1) were also inserted
into the same expression vector.
In the new isoforms, omission of exon E or exons E and F disrupts the known
ORF of CREM with translation initiation at the most 3' triplet in exon
2 (Figure 2). Instead,
an upstream ATG codon in exon
2 might serve as initiator codon in
CREM-
2-F-G-H-Ib, resulting in a novel N-terminal sequence of 22 amino
acids, which would then continue with the regular ORF in exon F
(Figure 2). In the second
isoform, CREM-
2-G-H-Ib, however, both of the start codons in exon
2 can only lead to translation of very short peptides terminating in
exon G. The potential protein products and their predicted molecular masses
(including the 3'-tag provided by the expression vector) are shown in
Figure 2.
|
2-F-G-H-Ib and
2-G-H-Ib in the
expression vector pcDNA/FLAG-His were subjected to in vitro
transcription/translation in order to analyze potential resulting proteins in
Western blotting with anti-FLAG M2 antibody. Isoforms CREM-
2-E-F-G-H-Ib
and CREM-
2-E-F-H-Ib were included for comparison. As shown in
Figure 3A, the
CREM-
2-F-G-H-Ib cDNA gives rise to proteins of 28 and 22.1 kd apparent
molecular weight. This indicates that the novel upstream ORF in exon
2
is translated to give rise to a full-length protein including part of the KID,
the transactivation domain
2, and the bZIP DBDII. The downstream ATG in
exon G is not utilized, as it would have resulted in the SS-CREM-
2-ß
isoform of 17.9 kd (Figure 2).
This isoform, however, is the only one detected as translation product from
2-G-H-Ib. The cDNAs
2-E-F-G-H-Ib and
2-E-F-H-Ib give rise
predominantly to products initiated in exon F (S-CREM-
2-ß, 22.1 kd;
S-CREM-ß, 15.9 kd). The 3' ATG in exon
2 is used very
inefficiently, as only a faint product of 29.3 kd and none of 23.1 kd are
detected (Figures 2 and
3).
|
2-G-H-Ib cDNA was much weaker in vivo than in vitro.
No signals were detected when analyzing the empty expression vector
pcDNA/FLAG-His.
Verification of Sequence-Specific DNA-Binding of CREM Isoforms![]()
To investigate whether the proteins visualized in Western blotting are able
to specifically bind to DNA, we performed EMSAs on in vitro translation
products of the CREM isoforms (Figure
4). A Cy5-labeled oligonucleotide carrying a CRE consensus
(TGACGTCA) served as the probe. Migration of free probe is seen in lane 1.
Using transcription/translation mix primed with empty expression vector
pcDNA/FLAG-His, 2 DNA/protein adducts were formed. The more slowly migrating
complex (*), which cannot be competed by a 300-fold excess of unlabeled CRE,
was also detectable with in vitro translation products of all CREM-isoforms.
It is nonspecific and formed by a component of the reaction mix. A faster
migrating complex (**) was also observed with all samples, including that
primed with empty vector. It was competed not only by an excess of consensus
CRE but also by the oligonucleotide carrying a mutated CRE. It can therefore
be concluded that it is formed by proteins from the reaction mixture which do
not bind to the core CRE sequence of the probe but to sequences flanking the
palindromic octamer.
|
2-E-F-G-H-Ib produced 3 complexes which were
supershifted by FLAG antibody, competed by CRE but not by CREmut, and likely
represent homo- and heterodimers of the 29.3 and 22.1 kd proteins
(Figure 4, lanes 47).
The 15.9 kd product of the
2-E-F-H-Ib cDNA resulted in 1 specific
faster migrating complex (lanes 811). The novel CREM cDNA
2-F-G-H-Ib produced 3 more slowly migrating products, likely
representing homo- and heterodimers of the 28 and 22.1 kd isoforms (lanes
1215), and the 17.9 kd isoform translated from the novel cDNA
2-G-H-Ib formed 1 specific complex of intermediate mobility (lanes
1619).
Verification of Functional Activity of CREM Isoforms In Vivo![]()
Having demonstrated sequence-specific DNA binding ability of CREM isoforms,
we subsequently determined their functional activity in vivo and transfected
SKUT-1B cells with a luciferase reporter construct pCRE/-36rPRL/luc3, an
expression vector for the catalytic subunit of PKA (pcDNA/Cß) or an
inactive mutant (pcDNA/Cßmut), and the CREM cDNAs or empty expression
vector (Figure 5). The active
PKA subunit Cß, but not the mutated form, strongly stimulated reporter
gene expression, due to phosphorylation of endogenous CRE binding proteins in
SKUT-1B cells. This Cß-dependent stimulation was significantly inhibited
by coexpression of CREM-
2-E-F-G-H-Ib,
2-E-F-H-Ib or novel
2-F-G-H-Ib, but not by the novel
2-G-H-Ib. This indicates that
protein isoforms translated from the first 3 cDNAs are predominantly
repressors. The 17.9-kd protein translated from the
2-G-H-Ib cDNA is
also predicted to be a repressor, as it lacks the KID, but the level of
expression in SKUT-1B cells is probably too low to produce a functional
response (compare Figure 3B,
lane 5).
|
| Discussion |
|---|
|
|
|---|
2-F-G-H-Ib and CREM-
2-G-H-Ib, and subjected them to
functional analyses.
Western blot analysis of the CREM-
2-F-G-H-Ib translation product
indicates that the novel upstream ORF in exon
2 is translated to give
rise to a full-length protein of 28 kd. Other proteins detected correspond to
previously described truncated S- or SS-CREM isoforms resulting from
downstream translation initiation
(Gellersen et al, 2002). It
has to be noted that predicted sizes of CREM protein isoforms in this study
compared to a previous report (Gellersen
et al, 2002) are approximately 2 kd larger due to a longer
3' tag provided by the expression vector employed in the present
study.
All alternative translation products potentially produced from the 4 CREM
cDNAs included in this study are predicted to have sequence-specific DNA
binding ability. This was confirmed in EMSA on a CRE consensus probe.
Remarkably, the relative mobility and the number of DNA/protein complexes
formed with the products of a particular cDNA reflected the relative mass and
number of protein isoforms detected by Western blot analysis. CREMs, like all
bZIP proteins, are known to bind to their palindromic target sequence as homo-
or heterodimers with other bZIP proteins, due to interaction via the leucine
zipper region (Walker and Habener,
1996). When a single product was detected by Western blot
analysis, a single homodimeric complex was formed in EMSA, for example by
S-CREM-ß (15.9 kd) or SS-CREM-
2-ß (17.9 kd) translated from
2-E-F-H-Ib or
2-G-H-Ib, respectively. When 2 products were
translated from a single cDNA, as was the case for
2-E-F-G-H-Ib and
2-F-G-H-Ib, 3 complexes were observed in EMSA, likely due to formation
of 2 different homodimers and 1 heterodimer. From our observations in the gel
shift study and the Western blot analyses of both in vitro translated and in
vivo expressed CREM-
2-F-G-H-Ib, we conclude that the proposed
alternative longer ORF in exon
2 is indeed expressed. It adds a novel
N-terminal sequence of 22 amino acids to the C-terminal part of the KID,
followed by the transactivation domain
2 and the bZIP/DBDII. The
resultant longer (L) protein of 28 kd (Figures
2A and
3) is readily detectable via
the 3' FLAG epitope, proving maintenance of the regular ORF downstream
of exon
2. This protein, which we designated
L-CREM-
2-
2-ß, engages in homo- and heterodimerization and
binds to a CRE.
It remains to be established if this novel protein is a transcriptional
activator or repressor. Activators are characterized by the presence of the
KID, 1 or both of the transactivation domains (
1,
2), and 1 of the 2
DBDs, whereas repressors lack a transactivation domain
(Walker et al, 1994;
Behr and Weinbauer, 2001).
While L-CREM-
2-
2-ß contains the
2 as a prerequisite to
be a transcriptional activator, it is not known at present if the truncated
KID (encoded by exon F only) suffices for PKA-mediated phosphorylation and
subsequent activation. The luciferase reporter gene assay does not allow
unambiguous conclusions, because transfection of the CREM-
2-F-G-H-Ib
cDNA results in simultaneous production of L-CREM-
2-
2-ß (28
kd) and S-CREM-
2-ß (22.1 kd), as shown by Western blot analysis of
SKUT-1B cell extracts. The latter isoform is more abundantly expressed in
transfected cells and may antagonize activation potential of the former. This
phenomenon was observed for transfected CREM-
2-E-F-G-H-Ib cDNA,
included as a control in this experiment. This cDNA gives rise to a small
amount of the established transcriptional activator
CREM-
2-
2-ß (29.3 kd) and, more abundantly, repressor
S-CREM-
2-ß (22.1 kd). The net result was inhibition of
PKA-Cß-stimulated CRE-driven reporter gene expression, indicating that
protein isoforms translated from the 3 cDNAs CREM-
2-E-F-G-H-Ib,
CREM-
2-E-F-H-Ib, and the novel CREM-
2-F-G-H-Ib are predominantly
repressors. The transcriptional activity of the 17.9-kd protein translated
from the CREM-
2-G-H-Ib cDNA, predicted to be a repressor because it
lacks the KID, could not be determined due to the low level of expression in
transfected cells.
In conclusion, we functionally characterized 2 novel CREM isoforms,
2-F-G-H and
2-G-H, which in contrast to known isoforms exhibit a
transactivation domain (encoded by exon G) but lack a kinase-inducible domain
(encoded by exons E and F), resulting in a disruption of the open reading
frame. Transcriptional activity of these isoforms was investigated in
transfected cells applying a CRE-driven luciferase reporter gene. Although
data do not allow us to clearly decide whether these isoforms represent
activators or repressors, electrophoretic mobility shift assays demonstrated
that translation products of both
2-F-G-H-Ib and
2-G-H-Ib cDNAs
are able to specifically bind to DNA. Both in vitro and in vivo protein
analyses, in addition, indicated that a novel upstream open reading frame in
exon
2 is translated from
2-F-G-H-Ib, giving rise to a
full-length protein. Finally, usage of downstream ATGs for translation
initiation could be observed in both isoforms. Although our data contribute to
shedding more light on the regulation of both CREM gene transcription and CREM
transcript translation, further studies will be necessary to unravel the
complex role of the variety of CREM activator and repressor isoforms for male
(in)fertility.
| References |
|---|
|
|
|---|
Behr R, Weinbauer GF. CREM activator and repressor isoforms in
human testis: sequence variations and inaccurate splicing during impaired
spermatogenesis. Mol Hum Reprod. 2000; 6: 967
972.
Blendy JA, Kaestner KH, Weinbauer GF, Nieschlag E, Schütz G. Severe impairment of spermatogenesis in mice lacking the CREM gene. Nature. 1996;380: 162 165.[CrossRef][Medline]
Blöcher S, Behr R, Weinbauer GF, Bergmann M, Steger K. Different CREM-isoform gene expression between equine and human normal and impaired spermatogenesis. Theriogenology. 2003; 60: 1357 1369.[CrossRef][Medline]
Blöcher S, Fink L, Bohle RM, Bergmann M, Steger K. CREM activator and repressor isoform expression in human male germ cells. Int J Androl. 2005; 28: 215 223.[CrossRef][Medline]
Daniel PB, Rohrbach L, Habener JF. Novel cyclic adenosine
3',5'-monophosphate (cAMP) response element modulator
isoforms expressed by two newly identified cAMP-responsive promoters active in
the testis. Endocrinology. 2000; 141: 3923
3930.
De Cesare D, Fimia GM, Sassone-Corsi P. CREM, a master-switch of the transcriptional cascade in male germ cells. J Endocrinol Invest. 2000;23: 592 596.[Medline]
Delmas V, Laoide BM, Masquilier D, de Groot RP, Foulkes NS,
Sassone-Corsi P. Alternative usage of initiation codons in mRNA encoding the
cAMP-responsive-element modulator generates regulators with opposite
functions. Proc Natl Acad Sci U S A. 1992; 89: 4226
4230.
Foulkes NS, Mellström B, Benusiglio E, Sassone-Corsi P. Developmental switch of CREM function during spermatogenesis: from antagonist to activator. Nature. 1992; 355: 80 84.[CrossRef][Medline]
Gellersen B, Kempf R, Sandhowe R, Weinbauer GF, Behr R. Novel
leader exons of the cyclic adenosine 3',5'-monophosphate response
element modulator (CREM) gene, transcribed from promoters P3 and P4, are
highly testis-specific in primates. Mol Hum Reprod. 2002; 8: 965
976.
Gellersen B, Kempf R, Telgmann R. Human endometrial stromal cells
express novel isoforms of the transcriptional modulator CREM and up-regulate
ICER in the course of decidualization. Mol Endocrinol. 1997; 11: 97
113.
Masquilier D, Foulkes NS, Mattei M-G, Sassone-Corsi P. Human CREM gene: evolutionary conservation, chromosomal localization, and inducibility of the transcript. Cell Growth Differ. 1993; 4: 931 937.[Abstract]
Maurer RA. Both isoforms of the cAMP-dependent protein kinase
catalytic subunit can activate transcription of the prolactin gene.
J Biol Chem. 1989; 264: 6870
6873.
Montminy M. Transcriptional regulation by cyclic AMP. Annu Rev Biochem. 1997; 66: 807 822.[CrossRef][Medline]
Nantel F, Monaco L, Foulkes NS, Masquilier D, LeMeur M, Henriksén K, Dierich A, Parvinen M, Sassone-Corsi P. Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice. Nature. 1996;380: 159 162.[CrossRef][Medline]
Oliva R, Dixon GH. Vertebrate protamine genes and the histone-to-protamine replacement reaction. Prog Nucleic Acid Res Mol Biol. 1991;40: 25 94.[Medline]
Sassone-Corsi P. Transcription factors responsive to cAMP. Annu Rev Cell Dev Biol. 1995; 11: 355 377.[CrossRef][Medline]
Steger K. Possible predictive factors for ICSI? Molecular biology techniques in combination with therapeutic testicular biopsies. Andrologia. 2003; 35: 200 208.[CrossRef][Medline]
Steger K, Klonisch T, Gavenis K, Behr R, Schaller V, Drabent B,
Doenecke D, Nieschlag E, Bergmann M, Weinbauer GF. Round spermatids show
normal testis-specific H1t but reduced cAMP-responsive element modulator and
transition protein 1 expression in men with round-spermatid maturation arrest.
J Androl. 1999;20: 747
754.
Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M.
Classification of human B-ZIP proteins based on dimerization properties.
Mol Cell Biol. 2002; 22: 6321
6335.
Walker WH, Habener JF. Role of transcription factors CREB and CREM in cAMP-regulated transcription during spermatogenesis. Trends Endocrinol Metab. 1996;7: 133 138.
Walker WH, Sanborn BM, Habener JF. An isoform of transcription
factor CREM expressed during spermatogenesis lacks the phosphorylation domain
and represses cAMP-induced transcription. Proc Natl Acad Sci U S
A. 1994;91: 12423
12427.
Weinbauer GF, Behr R, Bergmann M, Nieschlag E. Testicular cAMP
responsive element modulator (CREM) protein is expressed in round spermatids
but is absent or reduced in men with round spermatid maturation arrest.
Mol Hum Reprod. 1998; 4: 9
15.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |